What Giazo treats: main uses and benefits

Giazo is an oral medication containing balsalazide disodium, a compound used specifically in the management of ulcerative colitis. It belongs to a class of drugs known as aminosalicylates, which work by reducing inflammation directly within the lining of the colon.

Primary Indication

Giazo is indicated for the treatment of mildly to moderately active ulcerative colitis. This condition is a chronic inflammatory bowel disease (IBD) characterized by irritation, inflammation, and ulcers in the large intestine and rectum.

Mechanism of Action and Benefits

The therapeutic effect of the medication is localized rather than systemic. Upon ingestion, the active ingredient is designed to pass through the upper digestive tract with minimal absorption. Once it reaches the colon, bacterial enzymes break it down to release 5-aminosalicylic acid (5-ASA), the active therapeutic component.

The primary benefits of this treatment include:

• Reduction of Inflammation: By delivering the active medicine directly to the site of the disease, it helps decrease the swelling and redness of the intestinal mucosa.
• Symptom Improvement: Effective management of active inflammation can lead to a reduction in common symptoms such as rectal bleeding, frequent bowel movements, and abdominal pain.
• Targeted Delivery: The formulation ensures that the highest concentration of the anti-inflammatory agent is available where it is needed most, minimizing its presence in the bloodstream.

Eligibility for Giazo (Balsalazide Disodium)

The official labeling for Giazo strictly defines the patient population for whom use is established and those for whom use is prohibited or restricted.

Eligibility Scope	Official Regulatory Statement
Populations Allowed	Male patients 18 years of age and older with mildly to moderately active ulcerative colitis.
Contraindications	Patients with known or suspected hypersensitivity to salicylates, aminosalicylates (e.g., mesalamine), or any component of the tablets must not use Giazo.
Limitations of Use	Effectiveness in female patients was not demonstrated in clinical trials. Safety and effectiveness of therapy beyond 8 weeks have not been established.
Age-Related Rules	Pediatric Use (under 18 years): Safety and effectiveness have not been established. Geriatric Use: Use with caution due to the greater likelihood of decreased organ function.

Eligibility is further restricted for those with underlying conditions. Caution is required in patients with a history of renal impairment or liver disease, necessitating functional evaluation before and during therapy. Pregnancy and lactation status also require caution; use during pregnancy is advised only if clearly needed, and caution must be exercised while nursing. Use is also advised against in patients at risk of upper gastrointestinal tract obstruction.

Interactions with other medicines and products

The interaction profile for Giazo (balsalazide disodium) is based on clinical and laboratory data documented in official government prescribing information. This information identifies specific pharmacodynamic and exposure-altering interactions, which define constraints for co-administration.

Clinically Significant Drug Interactions

Co-administration with specific medications carries documented risk and requires monitoring, as defined in regulatory labels:

• Immunosuppressive Agents: Combining Giazo with purine analogues, specifically Azathioprine or 6-Mercaptopurine (6-MP), is officially documented to increase the risk of serious blood dyscrasias and myelosuppression.
• Nephrotoxic Agents: The simultaneous use of Giazo with substances known to be damaging to the kidney, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), is associated with an increased risk of nephrotoxicity and potential for mesalamine-induced nephrolithiasis.

Metabolic and Procedural Interaction Notes

The compound and its metabolites are not expected to inhibit the metabolism of other medicinal products that are substrates of major hepatic cytochrome P450 enzymes, such as CYP1A2 or CYP3A4/5. This indicates a low likelihood of interaction through these metabolic pathways.

Separately, the drug's metabolite may interfere with the measurement of urinary normetanephrine, a documented substance interaction that can lead to a false positive result in laboratory testing. Furthermore, no mandatory timing separation is required, as the product is labeled for administration with or without food.

The function of Giazo is determined by the local conversion of the inactive compound, balsalazide, into the active molecule, mesalamine (5-ASA). The balsalazide prodrug remains stable during passage through the upper GI tract. In the large intestine, anaerobic bacteria cleave the molecule via the azoreductase enzyme, releasing mesalamine directly onto the colonic mucosa.

The mechanism of mesalamine involves inhibition of both the Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX) enzyme systems, leading to a reduced production of local mediators like prostaglandins and leukotrienes. Furthermore, the molecule modulates intracellular signaling by suppressing the Nuclear Factor-kappa B ( NF-kappa B) transcription factor and acting as a scavenger of Reactive Oxygen Species ( ROS). These molecular actions collectively lead to a reduction of inflammatory signals and oxidative stress impact on epithelial cells.

How to Use Giazo: Administration Guidelines

The usage of Giazo is structured by a specific set of instructions defining the route, schedule, and duration of the short-term course.

---

Administration Scope

Principle	Instruction
Route of Administration	Giazo is administered orally as a film-coated tablet.
Standard Dosage	The recommended total daily dosage is 6.6 grams, delivered as three 1.1 g tablets per dose.
Frequency and Timing	The total 6.6 g daily dose is divided and taken twice daily. The tablets may be taken with or without food, but adequate fluid intake is recommended with administration.
Preparation and Handling	For proper use, the tablets must be swallowed whole and must not be cut, broken, crushed, or chewed.
Treatment Duration	The medication is approved for a time-limited course of up to 8 weeks. Continued use beyond this period has not had its safety or effectiveness established.

---

Population and Contextual Rules

Specific guidelines exist for the context of use. The medication is explicitly limited to male patients 18 years of age and older. Effectiveness has not been demonstrated in female patients, and pediatric use is not established. Caution is advised when used in patients with hepatic impairment, and it is recommended that a patient's renal function be evaluated both prior to initiating therapy and periodically throughout the treatment course. This fixed protocol ensures the medication is used strictly within defined parameters.

Giazo (balsalazide disodium) is a pro-drug designed to release the anti-inflammatory compound mesalamine (5-ASA) primarily in the colon to manage inflammation associated with ulcerative colitis (UC).

Clinical evidence supporting its use for the treatment of mildly to moderately active UC is primarily drawn from controlled and open-label trials.

Key Findings from Clinical Trials

Clinical development included a placebo-controlled trial, an active-controlled trial comparing it to another mesalamine product, and an open-label extension study. These studies involved a total of 565 adult patients with mildly to moderately active UC.

• Duration of Study: The majority of evidence focuses on the treatment effects observed after an 8-week period. The safety and effectiveness of using Giazo beyond this 8-week period have not been established in these trials.

• Efficacy in Male Patients: In the placebo-controlled trial, clinical improvement was observed in the overall study population, with a statistically significant difference reported in favor of Giazo compared to placebo. However, a notable difference in response rates was observed between genders. The studies support the use of Giazo specifically for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older.

• Efficacy in Female Patients: Clinical trials did not demonstrate the effectiveness of Giazo for the treatment of female patients with mildly to moderately active UC. In one primary trial, the clinical improvement rate for females receiving placebo was numerically similar to or greater than that of females receiving Giazo.

Common Observations

The most commonly reported side effects in male patients receiving Giazo in the placebo-controlled trial included headache, nasopharyngitis (common cold symptoms), and anemia. The majority of observed adverse reactions were described as mild to moderate in severity. Clinical trial data also suggested that female patients reported adverse reactions more frequently than male patients.

Common questions about Giazo (FAQ)

Q: What is Giazo prescribed for?

A: Giazo is a medication approved for the treatment of acute anxiety disorders. It is classified as an SSRI (Selective Serotonin Reuptake Inhibitor).

Q: How long does Giazo typically take to begin showing effects?

A: While some individuals may experience initial changes in symptoms within two weeks, the full therapeutic effect of Giazo often takes four to eight weeks to be observed. It is important to continue treatment as directed by a healthcare provider, even if immediate relief is not noted.

Q: Are there common side effects associated with Giazo?

A: Yes, common side effects reported in clinical trials include mild nausea, dizziness, and dry mouth. Most side effects are often temporary and may decrease as the body adjusts to the medication. It is essential to discuss any persistent or severe side effects with a healthcare professional.

Q: What should I do if I miss a dose of Giazo?

A: If a dose is missed, take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to make up for a missed one. Always consult the specific instructions provided by your pharmacist or prescribing healthcare provider.

Q: Can Giazo be stopped suddenly?

A: Stopping Giazo abruptly is not recommended as it may lead to withdrawal symptoms. When discontinuing treatment, your healthcare provider will typically guide you through a gradual dosage reduction (tapering) to minimize potential adverse effects. Always consult your provider before making any changes to your treatment plan.

Q: Does Giazo interact with other medications or supplements?

A: Giazo has the potential to interact with various other medications, particularly other SSRIs, MAOIs (Monoamine Oxidase Inhibitors), and certain pain relievers (NSAIDs). It is crucial to provide your healthcare provider and pharmacist with a complete list of all prescription drugs, over-the-counter medications, and herbal supplements you are currently taking to check for possible interactions.

How to Store and Dispose of Giazo?

This medicine must be stored according to the official regulatory requirements to ensure its stability and effectiveness. Official labeling instructs that Giazo tablets be stored at Controlled Room Temperature.

---

Regulatory Storage Requirements

Storage Classification	Requirement
Temperature Range	20^circ to 25 C (68^circ to 77 F)
Permitted Excursions	15^circ to 30 C (59^circ to 86 F)

---

Disposal Information

To dispose of unused, expired, or unneeded Giazo, consult with a pharmacist or healthcare provider. Regulatory documents recommend seeking professional guidance to ensure the medicine is discarded according to authorized drug take-back programs or safe at-home disposal practices. Proper disposal is required to maintain environmental safety and prevent accidental access.